 BOSTON, Dec. 10, 2020 GLOBE NEWSWIRE -- X4 Pharmaceuticals, Inc. Nasdaq: XFOR, a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it has received Rare Pediatric Disease RPD Designation from the U.S. Food and Drug Administration FDA for its lead asset, mavorixafor, for the treatment of WHIM Warts, Hypogammaglobulinemia, Infections, and Myelokathexis syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene. Mavorixafor is currently being investigated in a global pivotal Phase 3 clinical trial, 4WHIM, for the treatment of WHIM syndrome in patients who are 12 years of age and older. 